Post by icemandios on Jun 14, 2021 12:49:55 GMT
Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June
PR Newswire
MARLBOROUGH, Mass. , June 14, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn , will participate in the AGP Summer Healthcare Symposium and a fireside chat hosted by H.C. Wainwright which are being held virtually on June 17, 2021 and June 22, 2021 , respectively.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
AGP Summer Healthcare Symposium:
Date: June 17, 2021
Event: One-on-one Meetings - organized through AGP representatives
H.C. Wainwright Fireside Chat:
Date: June 22, 2021
Time: 10:00 am EST
Webcast: Register Here
Interested parties may also access the H.C. Wainwright Fireside Chat webcast through the "Investors – Events and Presentations" section of the Company's website . The webcast will be archived and available on the Company's website for 90 days.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
MARLBOROUGH, Mass. , June 14, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn , will participate in the AGP Summer Healthcare Symposium and a fireside chat hosted by H.C. Wainwright which are being held virtually on June 17, 2021 and June 22, 2021 , respectively.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
AGP Summer Healthcare Symposium:
Date: June 17, 2021
Event: One-on-one Meetings - organized through AGP representatives
H.C. Wainwright Fireside Chat:
Date: June 22, 2021
Time: 10:00 am EST
Webcast: Register Here
Interested parties may also access the H.C. Wainwright Fireside Chat webcast through the "Investors – Events and Presentations" section of the Company's website . The webcast will be archived and available on the Company's website for 90 days.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .